ArticleBMC psychiatry2012
Treatment patterns in major depressive disorder after an inadequate response to first-line antidepressant treatment.
Article in BMC psychiatry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Structural and functional features of treatment-resistant depression: A systematic review and exploratory coordinate-based meta-analysis of neuroimaging studies.Psychiatry and clinical neurosciences · 2023Pooled it
- Effect of fecal microbiota transplant on symptoms of psychiatric disorders: a systematic review.BMC psychiatry · 2020Pooled it
- Double-blind, randomized, placebo-controlled pilot study of the phosphodiesterase-3 inhibitor cilostazol as an adjunctive to antidepressants in patients with major depressive disorder.CNS neuroscience & therapeutics · 2021Trial
- The Antidiabetic Metformin as an Adjunct to Antidepressants in Patients with Major Depressive Disorder: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Trial
- Explainable counterfactual reasoning in depression medication selection at multi-levels (personalized and population).BMC medical informatics and decision making · 2026Article
- Peer-led intervention for individuals with major depression: study protocol for a randomized controlled trial (SUPEERMood).BMC psychiatry · 2024Article
- Sex-dependent effects of early life stress on reinforcement learning and limbic cortico-striatal functional connectivity.Neurobiology of stress · 2023Article
- The Increasing Economic Burden with Additional Steps of Pharmacotherapy in Major Depressive Disorder.PharmacoEconomics · 2021Article
- Article
- Characteristics of patients with depression initiating or switching antidepressant treatment: baseline analyses of the PERFORM cohort study.BMC psychiatry · 2018Observational
- Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis.BMC psychiatry · 2017Article
- Understanding the Use of Atypical Antipsychotic Treatment for Major Depressive Disorder: An International Cross-Sectional Survey of Health Care Providers.Journal of clinical psychopharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of the study was to determine the most common pharmacological strategies used in the management of major depressive disorder (MDD) after an inadequate response to first-line antidepressant treatment in clinical practice.
methodsMulticenter, non-interventional study in adult outpatients with a DSM-IV-TR diagnosis of MDD and inadequate response to first-line antidepressant medication. Multiple logistic regression analyses were performed to identify independent factors associated with the adoption of a specific second-line strategy.
resultsA total of 273 patients were analyzed (mean age: 46.8 years, 67.8% female). Baseline mean Montgomery-Asberg Depression Rating Scale total score was 32.1 (95%CI 31.2-32.9). The most common strategies were: switching antidepressant medication (39.6%), augmentation (18.8%), and combination therapy (17.9%). Atypical antipsychotic drugs were the most commonly used agent for augmenting antidepressant effect. The presence of psychotic symptoms and the number of previous major depressive episodes were associated with the adoption of augmenting strategy (OR = 3.2 and 1.2, respectively).
conclusionThe switch to another antidepressant agent was the most common second-line therapeutic approach. Psychiatrists chose augmentation based on a worse patients' clinical profile (number of previous episodes and presence of psychotic symptoms).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.